Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan + Camrelizumab in HER2+ MIBC
NCT07639983Phase 2Not yet recruiting
- Sponsor
- Weifang Shengtai Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Jun 2028
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan and camrelizumab in muscle-invasive bladder cancer (MIBC), sponsored by Weifang Shengtai Pharmaceutical. Primary endpoint: Pathological Complete Response Rate at 1 year. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecancamrelizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07639983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639983.